A detailed history of China Universal Asset Management Co., Ltd. transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 13,676 shares of ZNTL stock, worth $54,020. This represents 0.01% of its overall portfolio holdings.

Number of Shares
13,676
Previous 8,343 63.92%
Holding current value
$54,020
Previous $34,000 47.06%
% of portfolio
0.01%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$2.9 - $4.57 $15,465 - $24,371
5,333 Added 63.92%
13,676 $50,000
Q2 2024

Jul 19, 2024

SELL
$4.09 - $16.13 $21,640 - $85,343
-5,291 Reduced 38.81%
8,343 $34,000
Q1 2024

Apr 29, 2024

BUY
$10.83 - $16.49 $58,980 - $89,804
5,446 Added 66.51%
13,634 $215,000
Q4 2023

May 21, 2024

SELL
$9.84 - $20.13 $53,588 - $109,627
-5,446 Reduced 39.94%
8,188 $124,000
Q4 2023

Jan 23, 2024

BUY
$9.84 - $20.13 $62,769 - $128,409
6,379 Added 352.63%
8,188 $124,000
Q3 2023

May 21, 2024

BUY
$19.63 - $28.29 $20,218 - $29,138
1,030 Added 132.22%
1,809 $36,000
Q3 2023

Oct 30, 2023

BUY
$19.63 - $28.29 $20,218 - $29,138
1,030 Added 132.22%
1,809 $36,000
Q2 2023

May 21, 2024

BUY
$17.41 - $30.05 $104 - $180
6 Added 0.78%
779 $21,000
Q2 2023

Jul 27, 2023

BUY
$17.41 - $30.05 $104 - $180
6 Added 0.78%
779 $22,000
Q1 2023

May 21, 2024

BUY
$16.14 - $24.94 $3,131 - $4,838
194 Added 33.51%
773 $13,000
Q1 2023

Apr 27, 2023

BUY
$16.14 - $24.94 $3,131 - $4,838
194 Added 33.51%
773 $13,000
Q4 2022

May 21, 2024

SELL
$18.07 - $25.6 $235,903 - $334,208
-13,055 Reduced 95.75%
579 $11,000
Q4 2022

Jan 31, 2023

BUY
$18.07 - $25.6 $813 - $1,152
45 Added 8.43%
579 $12,000
Q3 2022

Oct 21, 2022

BUY
$20.23 - $31.73 $10,802 - $16,943
534 New
534 $12,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $225M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.